Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth

Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on Amgen Inc. (NASDAQ:AMGN) but lowered the price target to $427 from $432.

Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth

The new price target still represents significant upside potential as the research firm expects the company to deliver top-line revenue growth for both 2026 and 2027. The new price target is also less dependent on key commercial products, including Repatha, Tezspire, and Evenity.

The research firm expects continued strength in the rare disease segment, especially Uplizna, to accelerate underlying growth. Uplizna sales were up 188% year over year to $262 million in the first quarter, driven by volume growth.

Tepezza, an FDA-approved prescription medication for treating Thyroid Eye Disease (TED) in adults, is also expected to drive the growth following strong Phase III data. In the first quarter, Tepezza sales increased 29% year over year to $490 million, driven by higher inventory levels.

Amgen Inc. (NASDAQ:AMGN) is a leading global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on treating serious illnesses in oncology, cardiology, bone health, inflammation, and rare diseases. As a pioneer in using living cells to create biologic medicines, Amgen serves millions of patients worldwide.

While we acknowledge the risk and potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Large-Cap Stock Picks with Highest Upside Potential and 12 Best Uranium Stocks to Buy According to Wall Street Analysts.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1